Study of Cetuximab + Irinotecan + S-1 as first line therapy in metastatic colorectal cancer with KRAS wild type
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000004580
- Lead Sponsor
- Tsuchiura kyodo general hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1. Sever myeloablation 2. Severe infectious disease 3. Sensory alteration or paresthesia interfering with function 4. A mental disorder, nucleus neuropathy, cerebrovascular neuropathy failure 5. Comorbidity or history of heart failure 6. Interstitial lung disease or pulmonary fibrosis 7. Prior radiotherapy for primary and metastases tumors 8. History of severe allergy 9. Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test 10. Sever comorbidity (renal failure, liver failure, hypertension, high calcium, etc) 11. Symptomatic brain metastases 12. Patient have metachronous multiple malignancy 13. Any other cases who are regarded as inadequate for study enrollmet by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method